Merlin.net vs Eko Low Ejection Fraction Tool (ELEFT)

Eko Low Ejection Fraction Tool (ELEFT) offers superior usability for its specific purpose by integrating AI-powered detection into a routine physical exam with an Eko digital stethoscope, providing results in approximately 15 seconds. This streamlined, non-invasive, point-of-care approach makes it highly efficient for frontline clinicians. While Merlin.net provides a comprehensive web-based platform for managing implanted cardiac devices, ELEFT's rapid, integrated diagnostic workflow for early detection offers a more immediate and impactful user experience for its intended use.

ELEFT provides significant clinical value by enabling early, non-invasive detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. This AI-powered tool has been clinically validated to improve detection rates and can lead to earlier intervention and better patient outcomes for a broad population at risk of heart failure. Merlin.net offers crucial remote monitoring and management for patients with existing implanted cardiac devices, but ELEFT's potential for widespread early diagnosis in primary care settings gives it a broader impact on public health.

Both tools require contacting the vendor for specific pricing, indicating a lack of transparency. However, Eko's SENSORAu2122 platform, which includes ELEFT, has secured a Category III CPT code for reimbursement, effective July 2025. This established pathway for reimbursement provides a clearer financial value proposition and facilitates broader adoption within healthcare systems, giving ELEFT an advantage in terms of recognized value.

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating strong regulatory and security foundations. Merlin.net, from Abbott, explicitly details its EHRDirectu2122 data transfer feature, supporting HL7 standards and compatibility with major EHR systems like EpicCareu2122 and Allscriptsu2122. Furthermore, its ISO 27001 certification and SOC 2 Type II report provide concrete evidence of robust data security and interoperability, giving it an edge in enterprise integration capabilities.

ELEFT demonstrates greater innovation by applying an FDA-cleared AI algorithm to a digital stethoscope for the early detection of low ejection fraction during routine physical exams. This transforms a common diagnostic tool into a powerful screening device, disrupting traditional diagnostic pathways and enabling proactive care at the point of care. While Merlin.net offers advanced remote monitoring, ELEFT's novel application of AI for early, non-invasive diagnostics represents a more significant innovative leap.

Both companies provide comprehensive support and documentation for their respective platforms. Abbott offers detailed help manuals, EHR integration FAQs, and direct technical support via phone and email for Merlin.net. Similarly, Eko Health provides a robust help center for its SENSORAu2122 platform, including guides for various user roles, email support, and scheduled phone calls. Given the extensive resources offered by both, neither tool clearly surpasses the other in this dimension.